Comments on ‘Joint modeling of survival and longitudinal non-survival data: current methods and issues. Report of the DIA Bayesian Joint Modeling Working Group’

2015 ◽  
Vol 34 (14) ◽  
pp. 2196-2197 ◽  
Author(s):  
Dimitris Rizopoulos
2015 ◽  
Vol 34 (14) ◽  
pp. 2202-2203 ◽  
Author(s):  
A. Lawrence Gould ◽  
Mark Ernest Boye ◽  
Michael J. Crowther ◽  
Joseph G. Ibrahim ◽  
George Quartey ◽  
...  

2014 ◽  
Vol 34 (14) ◽  
pp. 2181-2195 ◽  
Author(s):  
A. Lawrence Gould ◽  
Mark Ernest Boye ◽  
Michael J. Crowther ◽  
Joseph G. Ibrahim ◽  
George Quartey ◽  
...  

2018 ◽  
Vol 28 (10-11) ◽  
pp. 3392-3403 ◽  
Author(s):  
Jue Wang ◽  
Sheng Luo

Impairment caused by Amyotrophic lateral sclerosis (ALS) is multidimensional (e.g. bulbar, fine motor, gross motor) and progressive. Its multidimensional nature precludes a single outcome to measure disease progression. Clinical trials of ALS use multiple longitudinal outcomes to assess the treatment effects on overall improvement. A terminal event such as death or dropout can stop the follow-up process. Moreover, the time to the terminal event may be dependent on the multivariate longitudinal measurements. In this article, we develop a joint model consisting of a multidimensional latent trait linear mixed model (MLTLMM) for the multiple longitudinal outcomes, and a proportional hazards model with piecewise constant baseline hazard for the event time data. Shared random effects are used to link together two models. The model inference is conducted using a Bayesian framework via Markov chain Monte Carlo simulation implemented in Stan language. Our proposed model is evaluated by simulation studies and is applied to the Ceftriaxone study, a motivating clinical trial assessing the effect of ceftriaxone on ALS patients.


2018 ◽  
Vol 74 (2) ◽  
pp. 226-232 ◽  
Author(s):  
Melissa Y Wei ◽  
Mohammed U Kabeto ◽  
Andrzej T Galecki ◽  
Kenneth M Langa

Abstract Background Multimorbidity is common among older adults and strongly associated with physical functioning decline and increased mortality. However, the full spectrum of direct and indirect effects of multimorbidity on physical functioning and survival has not been quantified. We aimed to determine the longitudinal relationship of multimorbidity on physical functioning and quantify the impact of multimorbidity and multimorbidity-attributed changes in physical functioning on mortality risk. Methods The Health and Retirement Study (HRS) is a nationally representative population-based prospective cohort of adults aged 51 or older. In 2000, participants were interviewed about physician-diagnosed chronic conditions, from which their multimorbidity-weighted index (MWI) was computed. Between 2000 and 2011, participants reported their current physical functioning using a modified Short Form-36. With MWI as a time-varying exposure, we jointly modeled its associations with physical functioning and survival. Results The final sample included 74,037 observations from 18,174 participants. At baseline, participants had a weighted mean MWI of 4.6 ± 4.2 (range 0–36.8). During follow-up, physical functioning declined: −1.72 (95% confidence interval [CI] −1.77, −1.67, p < .001) HRS physical functioning units per point MWI in adjusted models. Over follow-up, 6,362 (34%) participants died. Mortality risk increased 8% (hazard ratio 1.08, 95% CI 1.07–1.08, p < .001) per point MWI in adjusted models. Across all population subgroups, MWI was associated with greater physical functioning decline and mortality risk. Conclusions Multimorbidity and its associated decline in physical functioning were significantly associated with increased mortality. These associations can be predicted with an easily interpreted and applied multimorbidity index that can better identify and target adults at increased risk for disability and death.


2011 ◽  
Vol 30 (18) ◽  
pp. 2295-2309 ◽  
Author(s):  
Liddy M. Chen ◽  
Joseph G. Ibrahim ◽  
Haitao Chu

Sign in / Sign up

Export Citation Format

Share Document